Glen Eagle Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $88.1K | Buy |
114
+37
| +48% | +$28.3K | 0.01% | 353 |
|
|
2025
Q4 | $59.4K | Sell |
77
-40
| -34% | -$27.2K | 0.01% | 415 |
|
|
2025
Q3 | $65.8K | Sell |
117
-9
| -7% | -$5.09K | 0.01% | 402 |
|
|
2025
Q2 | $66.2K | Sell |
126
-10
| -7% | -$5.58K | 0.01% | 377 |
|
|
2025
Q1 | $86.3K | Hold |
136
| – | – | 0.01% | 328 |
|
|
2024
Q4 | $96.9K | Hold |
136
| – | – | 0.02% | 311 |
|
|
2024
Q3 | $143K | Hold |
136
| – | – | 0.02% | 275 |
|
|
2024
Q2 | $143K | Buy |
136
+10
| +8% | +$9.69K | 0.03% | 263 |
|
|
2024
Q1 | $121K | Sell |
126
-2
| -2% | -$1.9K | 0.02% | 284 |
|
|
2023
Q4 | $112K | Hold |
128
| – | – | 0.02% | 284 |
|
|
2023
Q3 | $105K | Hold |
128
| – | – | 0.02% | 286 |
|
|
2023
Q2 | $92K | Hold |
128
| – | – | 0.02% | 298 |
|
|
2023
Q1 | $105K | Sell |
128
-1
| -0.8% | -$754 | 0.03% | 278 |
|
|
2022
Q4 | $93.1K | Buy |
129
+1
| +0.8% | +$738 | 0.03% | 286 |
|
|
2022
Q3 | $88.2K | Sell |
128
-8
| -6% | -$5.04K | 0.03% | 278 |
|
|
2022
Q2 | $80.4K | Hold |
136
| – | – | 0.02% | 305 |
|
|
2022
Q1 | $95K | Hold |
136
| – | – | 0.02% | 288 |
|
|
2021
Q4 | $85.9K | Hold |
136
| – | – | 0.02% | 301 |
|
|
2021
Q3 | $82.3K | Sell |
136
-5
| -4% | -$3.1K | 0.02% | 300 |
|
|
2021
Q2 | $78.8K | Sell |
141
-60
| -30% | -$30.4K | 0.02% | 303 |
|
|
2021
Q1 | $95.1K | Sell |
201
-50
| -20% | -$24.3K | 0.03% | 258 |
|
|
2020
Q4 | $121K | Sell |
251
-9
| -3% | -$4.86K | 0.05% | 213 |
|
|
2020
Q3 | $146K | Hold |
260
| – | – | 0.07% | 183 |
|
|
2020
Q2 | $162K | Buy |
260
+108
| +71% | +$61.3K | 0.08% | 167 |
|
|
2020
Q1 | $74.2K | Buy |
152
+107
| +238% | +$44.1K | 0.05% | 223 |
|
|
2019
Q4 | $16.9K | Hold |
45
| – | – | 0.01% | 491 |
|
|
2019
Q3 | $12.5K | Hold |
45
| – | – | 0.01% | 475 |
|
|
2019
Q2 | $14.1K | Hold |
45
| – | – | 0.01% | 450 |
|
|
2019
Q1 | $18.5K | Hold |
45
| – | – | 0.01% | 394 |
|
|
2018
Q4 | $16.8K | Hold |
45
| – | – | 0.01% | 386 |
|
|
2018
Q3 | $18.2K | Hold |
45
| – | – | 0.01% | 392 |
|
|
2018
Q2 | $15.5K | Hold |
45
| – | – | 0.01% | 394 |
|
|
2018
Q1 | $15.5K | Hold |
45
| – | – | 0.01% | 373 |
|
|
2017
Q4 | $16.9K | Hold |
45
| – | – | 0.01% | 359 |
|
|
2017
Q3 | $20.1K | Hold |
45
| – | – | 0.02% | 334 |
|
|
2017
Q2 | $22.1K | Hold |
45
| – | – | 0.02% | 298 |
|
|
2017
Q1 | $17.4K | Hold |
45
| – | – | 0.01% | 301 |
|
|
2016
Q4 | $16.5K | Buy |
+45
| New | +$17.1K | 0.01% | 292 |
|
Other funds holding REGN
VCM
N
Glen Eagle Advisors's REGN Position: Q1 2026 in Review
Glen Eagle Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 48% in Q1 2026, buying an estimated $28.3K and bringing the position to 114 shares worth $88.1K. The position accounts for 0.01% of the portfolio, ranked #353.
Glen Eagle Advisors first reported a position in REGN in Q4 2016 and has held it in 38 quarters since. The position peaked at $162K in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Glen Eagle Advisors held 114 shares of Regeneron Pharmaceuticals worth $88.1K as of Q1 2026.
- Glen Eagle Advisors bought 37 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $28.3K.
- Regeneron Pharmaceuticals made up 0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #353 holding.
- Glen Eagle Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's Regeneron Pharmaceuticals position peaked at $162K in Q2 2020.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.